The article outlines the emerging trend of using retatrutida, a weight loss product presented in a pen form, which has been reported by social media users. Despite its growing popularity among some individuals seeking to lose weight, retatrutida remains unapproved in Brazil and other countries globally, still undergoing clinical studies. Regulatory authorities like Brazil's Anvisa and the FDA in the United States have taken steps to prohibit its sale and use, noting serious health risks associated with its consumption.

In early 2023, Anvisa mandated the seizure of all products containing retatrutida, while the FDA emphasized that it should not be included in compounding practices due to its unapproved status. Similarly, the European Medicines Agency (EMA) has also warned against the illegal sale of such weight loss pens, highlighting the importance of regulatory oversight in drug approvals. Such measures reflect the potential dangers posed by unregulated products in the market.

The risks associated with using unapproved weight loss products like retatrutida include severe health complications, ineffective treatment outcomes, and dangerous interactions with other medications. The article serves as a warning for consumers against the allure of quick-fix solutions for weight loss that lack scientific backing and regulatory approval.